Grazax

GRAZAX is a sublingual tablet containing 225 S.U. of Phleum pratense (timothy grass) allergen extract, marketed for the treatment of grass pollen allergy. It is an immunotherapy product approved in the EU. The tablet is placed under the tongue daily to induce immune tolerance to grass pollen, helping reduce symptoms of seasonal allergic rhinitis in patients with confirmed grass‑pollen sensitivity through a structured dosing schedule.

Grazax is indicated for the management of grass‑pollen–related allergic conditions.

- Seasonal allergic rhinitis (hay fever) caused by grass pollen. - Allergic conjunctivitis triggered by grass pollen exposure. - Prevention of symptom recurrence during the grass pollen season. - Use as part of a comprehensive allergy management plan in patients with confirmed grass‑pollen sensitivity.

Side effects reported with sublingual grass pollen immunotherapy vary in frequency and severity.

Common: - Mild itching or irritation of the mouth or throat. - Transient oral swelling or tingling sensation. - Mild gastrointestinal discomfort such as nausea. - Localized ear or nasal itching.

Serious: - Persistent or severe oral swelling that interferes with breathing. - Anaphylactic reaction requiring emergency medical attention. - Severe asthma exacerbation triggered by the tablet.

Before starting Grazax, certain precautions should be considered to ensure safe use.

- Confirmed diagnosis of grass‑pollen allergy by skin test or specific IgE. - Not recommended for patients with uncontrolled asthma or severe respiratory disease. - Use under medical supervision, especially during the first dose. - Avoid if you have a history of severe allergic reactions to any component of the tablet. - Discuss use during pregnancy or breastfeeding with a healthcare professional. - Keep the tablet out of reach of children.

Grazax may interact with other medications or substances that affect the immune system or allergic response.

Avoid: - Concurrent use of other allergen immunotherapy products without medical guidance. - Systemic corticosteroids at high doses during the treatment period.

Use with caution: - Beta‑agonist inhalers for asthma; monitor symptoms closely. - Antihistamines may mask early signs of an allergic reaction. - ACE inhibitors or NSAIDs if they have a known propensity to cause angio‑edema.